Miami (November 11, 2025) – Men and women with chronic obstructive pulmonary disease (COPD), bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease report differences in symptoms, mental ...

GERMANTOWN, Md., Dec. 10, 2025 /PRNewswire/ -- The HealthWell Foundation®, an independent non-profit charitable organization that provides financial assistance for underinsured Americans, has opened a ...

Miami (October 23, 2025) – The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at CHEST 2025, held October ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...

Please provide your email address to receive an email when new articles are posted on . Adults with a long-term smoking history suspected to have bronchiectasis faced an elevated mortality risk ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...

Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...